FDA panel recommends two new cancer drugs for approval.
Open Access
- 7 February 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 93 (3) , 175-176
- https://doi.org/10.1093/jnci/93.3.175
Abstract
The U.S. Food and Drug Administration in January approved the drug Femara for first-line treatment of advanced breast cancer. The approval of the aromatase inhibitor was based on the recommendations of the agency’s panel of cancer experts.Keywords
This publication has 0 references indexed in Scilit: